MBX Biosciences, Inc.
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -104.29M | -86.61M | -86.97M | -80.50M | -77.02M |
| Total Depreciation and Amortization | 453.00K | 435.00K | 448.00K | 346.00K | 371.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.18M | 9.41M | 5.00M | 3.08M | 2.17M |
| Change in Net Operating Assets | 6.99M | -719.00K | 1.58M | -620.00K | 3.66M |
| Cash from Operations | -82.67M | -77.48M | -79.95M | -77.69M | -70.81M |
| Capital Expenditure | -2.53M | -2.34M | -1.93M | -1.23M | -886.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -178.27M | -181.69M | -81.78M | -19.85M | -138.04M |
| Cash from Investing | -180.80M | -184.03M | -83.71M | -21.08M | -138.92M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 279.29M | 278.17M | 190.36M | 189.60M | 176.04M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 0.00 | 63.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.28M | -1.15M | -771.00K | -581.00K | -2.52M |
| Cash from Financing | 278.02M | 277.02M | 189.59M | 189.02M | 237.01M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.55M | 15.52M | 25.94M | 90.26M | 27.28M |